Exact Mass: 516.2332128

Exact Mass Matches: 516.2332128

Found 500 metabolites which its exact mass value is equals to given mass value 516.2332128, within given mass tolerance error 0.05 dalton. Try search metabolite list with more accurate mass tolerance error 0.01 dalton.

Eriojaposide B

3,5,5-trimethyl-4-[(1E)-3-[(3,4,5-trihydroxy-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]but-1-en-1-yl]cyclohex-2-en-1-one

C25H40O11 (516.257049)


Eriojaposide B is found in fruits. Eriojaposide B is a constituent of Eriobotrya japonica (loquat). Constituent of Eriobotrya japonica (loquat). Eriojaposide B is found in fruits. D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

   

Ispinesib

Ispinesib

C30H33ClN4O2 (516.2291908000001)


C274 - Antineoplastic Agent > C186664 - Cytotoxic Chemotherapeutic Agent > C273 - Antimitotic Agent

   

Udenafil

3-(1-Methyl-7-oxo-3-propyl-4,7-dihydro-1H-pyrazolo(4,3-D)pyrimidin-5-yl)-N-(2-(1-methyl-2-pyrrolidinyl)ethyl)-4-propoxybenzenesulfonamide

C25H36N6O4S (516.2518616)


Udenafil is a new phosphodiesterase type 5 (PDE5) inhibitor used to treat erectile dysfunction (ED). It has been approved in South Korea and will be marketed under the brand name Zydena. It is not yet approved for use in the U.S., E.U., or Canada. G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor

   

Austalide A

13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0^{1,17}.0^{4,16}.0^{6,14}.0^{8,12}]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359206)


Austalide A is a metabolite of Aspergillus ustu Metabolite of Aspergillus ustus.

   

Perindoprilat glucuronide

(2R,3R,4S,5S,6R)-2-[(2S,3aS,7aS)-1-{2-[(1-carboxypropyl)amino]propanoyl}-octahydro-1H-indole-2-carbonyloxy]-3,4,5-trihydroxy-6-methyloxane-2-carboxylic acid

C23H36N2O11 (516.2318986)


Perindoprilat glucuronide is a metabolite of perindopril. Perindopril, or perindopril arginine, (trade names include Coversyl and Aceon) is a long-acting ACE inhibitor. Perindopril is used to treat high blood pressure, heart failure or stable coronary artery disease. It is also available in a generic form, perindopril erbumine. (Wikipedia)

   

1-(3-Methylphenyl)-3-[(3R)-1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-3H-1,4-benzodiazepin-3-yl]urea

3-(3-methylphenyl)-1-{1-[2-(2-methylphenyl)-2-oxoethyl]-2-oxo-5-phenyl-2,3-dihydro-1H-1,4-benzodiazepin-3-yl}urea

C32H28N4O3 (516.2161298)


   

Mayzent

1-({4-[1-({[4-cyclohexyl-3-(trifluoromethyl)phenyl]methoxy}imino)ethyl]-2-ethylphenyl}methyl)azetidine-3-carboxylic acid

C29H35F3N2O3 (516.2599636)


   

Ispinesib

N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxo-3,4-dihydroquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

C30H33ClN4O2 (516.2291908000001)


   

PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 14,15-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z)-13-(3-pentyloxiran-2-yl)trideca-5,8,11-trienoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0), in particular, consists of one chain of one 14,15-epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 11,12-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z)-10-{3-[(2Z)-oct-2-en-1-yl]oxiran-2-yl}deca-5,8-dienoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0), in particular, consists of one chain of one 11,12-epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:3(5Z,11Z,14Z)-O(8,9))

[(2R)-3-(acetyloxy)-2-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:3(5Z,11Z,14Z)-O(8,9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(5Z,11Z,14Z)-O(8,9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 8,9--epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z)-7-{3-[(2Z,5Z)-undeca-2,5-dien-1-yl]oxiran-2-yl}hept-5-enoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0), in particular, consists of one chain of one 8,9--epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:3(8Z,11Z,14Z)-O(5,6))

[(2R)-3-(acetyloxy)-2-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:3(8Z,11Z,14Z)-O(5,6)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:3(8Z,11Z,14Z)-O(5,6)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5,6-epoxyeicosatrienoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0)

[(2R)-2-(acetyloxy)-3-[(4-{3-[(2Z,5Z,8Z)-tetradeca-2,5,8-trien-1-yl]oxiran-2-yl}butanoyl)oxy]propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0), in particular, consists of one chain of one 5,6-epoxyeicosatrienoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 20-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,14Z)-20-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0), in particular, consists of one chain of one 20-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

[(2R)-3-(acetyloxy)-2-{[(5R,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 5-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5S,6E,8Z,11Z,14Z)-5-hydroxyicosa-6,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0), in particular, consists of one chain of one 5-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,14Z,19S)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 19-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,14Z,19R)-19-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0), in particular, consists of one chain of one 19-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,14Z,18R)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 18-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,14Z,18S)-18-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0), in particular, consists of one chain of one 18-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 17-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,14Z)-17-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0), in particular, consists of one chain of one 17-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,14Z,16R)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 16-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,14Z,16S)-16-hydroxyicosa-5,8,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0), in particular, consists of one chain of one 16-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,11Z,13E,15S)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 15-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,11Z,13E,15R)-15-hydroxyicosa-5,8,11,13-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0), in particular, consists of one chain of one 15-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

[(2R)-3-(acetyloxy)-2-{[(5Z,8Z,10E,12S,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 12-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5Z,8Z,10E,12R,14Z)-12-hydroxyicosa-5,8,10,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0), in particular, consists of one chain of one 12-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

[(2R)-3-(acetyloxy)-2-{[(5E,8Z,11R,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 11-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5E,8Z,11S,12Z,14Z)-11-hydroxyicosa-5,8,12,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0), in particular, consists of one chain of one 11-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9))

[(2R)-3-(acetyloxy)-2-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9)), in particular, consists of one chain of one acetyl at the C-1 position and one chain of 9-Hydroxyeicosatetraenoyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0)

[(2R)-2-(acetyloxy)-3-{[(5E,7Z,11Z,14Z)-9-hydroxyicosa-5,7,11,14-tetraenoyl]oxy}propoxy]phosphonic acid

C25H41O9P (516.2488066)


PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0) is an oxidized phosphatidic acid (PA). Oxidized phosphatidic acids are glycerophospholipids in which a phosphate moiety occupies a glycerol substitution site and at least one of the fatty acyl chains has undergone oxidation. As all oxidized lipids, oxidized phosphatidic acids belong to a group of biomolecules that have a role as signaling molecules. The biosynthesis of oxidized lipids is mediated by several enzymatic families, including cyclooxygenases (COX), lipoxygenases (LOX) and cytochrome P450s (CYP). Non-enzymatically oxidized lipids are produced by uncontrolled oxidation through free radicals and are considered harmful to human health (PMID: 33329396). As is the case with diacylglycerols, phosphatidic acids can have many different combinations of fatty acids of varying lengths, saturation and degrees of oxidation attached at the C-1 and C-2 positions. PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0), in particular, consists of one chain of one 9-Hydroxyeicosatetraenoyl at the C-1 position and one chain of acetyl at the C-2 position. Phospholipids are ubiquitous in nature and are key components of the lipid bilayer of cells, as well as being involved in metabolism and signaling. Similarly to what occurs with phospholipids, the fatty acid distribution at the C-1 and C-2 positions of glycerol within oxidized phospholipids is continually in flux, owing to phospholipid degradation and the continuous phospholipid remodeling that occurs while these molecules are in membranes. Oxidized PAs can be synthesized via three different routes. In one route, the oxidized PA is synthetized de novo following the same mechanisms as for PAs but incorporating oxidized acyl chains (PMID: 33329396). An alternative is the transacylation of one of the non-oxidized acyl chains with an oxidized acylCoA (PMID: 33329396). The third pathway results from the oxidation of the acyl chain while still attached to the PA backbone, mainly through the action of LOX (PMID: 33329396).

   

Strictosidinic acid

(2S,3R,4S)-3-ethenyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

C26H32N2O9 (516.2107702)


Annotation level-3 Strictosidinic acid is a natural product found in Strychnos axillaris, Hunteria zeylanica, and other organisms with data available.

   
   

Ejap 2

[3R-(3alpha,5beta,5aalpha,6alpha,9alpha,9aalpha,10R*)]- 5a-[(Acetyloxy)methyl]octahydro-2,2,9-trimethyl-2H-3,9a-methano-1-benzoxepin-5,6,10-triol 6,10-diacetate 5-benzoate

C28H36O9 (516.2359206)


   

Vaalens 5

[3R-[3alpha,5beta(E),5aalpha,6alpha,9beta,9aalpha,10R*]]-10-(Acetyloxy)octahydro-9-hydroxy-6-[(hydroxyacetyl)oxy]-2,2,5a,9-tetramethyl-2H-3,9a-methano-1-benzoxepin-5-yl ester 3-phenyl-2-propenoic acid

C28H36O9 (516.2359206)


   
   
   
   

Euchrenone b11

5,5-Dihydroxy-2-methoxy-6-prenyl-(2,3:7,8),(2,3:4,3)-bis(6,6-dimethylpyrano)isoflavone

C31H32O7 (516.2147921999999)


   
   

Triptogelin D-1|triptogelin D1

Triptogelin D-1|triptogelin D1

C28H36O9 (516.2359206)


   

Citreohybriddione A

Citreohybriddione A

C28H36O9 (516.2359206)


   

(1alpha,2beta,8beta,9beta)-1,2,8-tris(acetyloxy)-9-(benzoyloxy)dihydro-beta-agarofuran|rel-octahydro-2,2,5a,9-tetramethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,6,7-triacetate 5-benzoate

(1alpha,2beta,8beta,9beta)-1,2,8-tris(acetyloxy)-9-(benzoyloxy)dihydro-beta-agarofuran|rel-octahydro-2,2,5a,9-tetramethyl-2H-3,9a-methano-1-benzoxepin-4,5,6,7-tetrol 4,6,7-triacetate 5-benzoate

C28H36O9 (516.2359206)


   

9beta-amoorastatin

9beta-amoorastatin

C28H36O9 (516.2359206)


   

1,6,14-Triacetoxy-2,9-dibenzoyloxydihydro-alpha-agarofuran

1,6,14-Triacetoxy-2,9-dibenzoyloxydihydro-alpha-agarofuran

C28H36O9 (516.2359206)


   

1beta,6alpha,8alpha-triacetoxy-9beta-benzoyloxy-beta-dihydroagarofuran

1beta,6alpha,8alpha-triacetoxy-9beta-benzoyloxy-beta-dihydroagarofuran

C28H36O9 (516.2359206)


   

(6S,7E,9R)-6,9-dihydroxy-4,7-megastigmadien-3-one 9-O-[alpha-L-arabinopyranosyl-(1 -> 6)-beta-D-glucopyranoside]

(6S,7E,9R)-6,9-dihydroxy-4,7-megastigmadien-3-one 9-O-[alpha-L-arabinopyranosyl-(1 -> 6)-beta-D-glucopyranoside]

C25H40O11 (516.257049)


   

Mitraphyllic acid (16鈥樏傗垎1)-??-D-gluco-pyranosyl ester

Mitraphyllic acid (16鈥樏傗垎1)-??-D-gluco-pyranosyl ester

C26H32N2O9 (516.2107702)


   

schilancidilactone A

schilancidilactone A

C28H36O9 (516.2359206)


   

5-hydroxy-6-(4-cinnamoyl-3-methyl-1-oxobutyl)-4-n-propyl-2,2-dimethyl-2H,6H-benzo[1.2-b:3,4-b]-dipyran-2-one|7-hydroxy-8-(4-cinnamoyl-3-methyl-1-oxobutyl)-4-n-propyl-2,2-dimethyl-2H,6H-benzo[1.2-b:3,4-b]-dipyran-2-one

5-hydroxy-6-(4-cinnamoyl-3-methyl-1-oxobutyl)-4-n-propyl-2,2-dimethyl-2H,6H-benzo[1.2-b:3,4-b]-dipyran-2-one|7-hydroxy-8-(4-cinnamoyl-3-methyl-1-oxobutyl)-4-n-propyl-2,2-dimethyl-2H,6H-benzo[1.2-b:3,4-b]-dipyran-2-one

C31H32O7 (516.2147921999999)


   

1alpha,6alpha,14-triacetoxy-9beta-benzoyloxydihydro-beta-agarofuran

1alpha,6alpha,14-triacetoxy-9beta-benzoyloxydihydro-beta-agarofuran

C28H36O9 (516.2359206)


   

5-Hydroxy-8,8-dimethyl-10-(3-methyl-2-butenyl)-3-(2,2-dimethyl-5-methoxy-8-hydroxy-2H-1-benzopyran-6-yl)-4H,8H-benzo[1,2-b:5,4-b]dipyran-4-one

5-Hydroxy-8,8-dimethyl-10-(3-methyl-2-butenyl)-3-(2,2-dimethyl-5-methoxy-8-hydroxy-2H-1-benzopyran-6-yl)-4H,8H-benzo[1,2-b:5,4-b]dipyran-4-one

C31H32O7 (516.2147921999999)


   

1alpha-cinnamoyloxy-6beta,9beta-diacetoxy-2beta,4beta-dihydroxydihydro-beta-agarofuran|6,9-Di-Ac,1-cinnamoyl-1,2,4,6,9-Pentahydroxydihydro-beta-agarofuran

1alpha-cinnamoyloxy-6beta,9beta-diacetoxy-2beta,4beta-dihydroxydihydro-beta-agarofuran|6,9-Di-Ac,1-cinnamoyl-1,2,4,6,9-Pentahydroxydihydro-beta-agarofuran

C28H36O9 (516.2359206)


   

(22SR,23SR,24RS,25SR)-5alpha,6beta:12alpha,22:21,24-triepoxy-12beta,17beta,25-trihydroxy-1-oxo-with-2-en-26,23-olide|jaborosalactone 36

(22SR,23SR,24RS,25SR)-5alpha,6beta:12alpha,22:21,24-triepoxy-12beta,17beta,25-trihydroxy-1-oxo-with-2-en-26,23-olide|jaborosalactone 36

C28H36O9 (516.2359206)


   
   

(1S,7S,8S,9S)-10-chloro-11-(3-hydroxyisovaleroxy)-1,7-diisovaleroxyvaltrate chlorohydrin|chlorovaltrate L

(1S,7S,8S,9S)-10-chloro-11-(3-hydroxyisovaleroxy)-1,7-diisovaleroxyvaltrate chlorohydrin|chlorovaltrate L

C25H37ClO9 (516.2125982)


   

wuweizidilactone N

wuweizidilactone N

C28H36O9 (516.2359206)


   

aspergillide A|aspergillipeptide A

aspergillide A|aspergillipeptide A

C26H36N4O7 (516.2583866)


   

2,2-Di-O-Me-betabeta-D-Galactopyranosyl-(1?4)-beta-D-galactopyranosyl-(1?4)-L-rhamnose

2,2-Di-O-Me-betabeta-D-Galactopyranosyl-(1?4)-beta-D-galactopyranosyl-(1?4)-L-rhamnose

C20H36O15 (516.2054106)


   

1beta,8beta,13-Triacetoxy-9beta-benzoyloxy-beta-dihydroagarofuran

1beta,8beta,13-Triacetoxy-9beta-benzoyloxy-beta-dihydroagarofuran

C28H36O9 (516.2359206)


   
   

1beta,2beta,6alpha-triacetoxy-9alpha-benzoyloxy-beta-dihydroagarofuran|1beta,2beta,6alpha-triacetoxy-9alpha-benzoyloxydihydro-beta-agarofuran|triptogelin C-1

1beta,2beta,6alpha-triacetoxy-9alpha-benzoyloxy-beta-dihydroagarofuran|1beta,2beta,6alpha-triacetoxy-9alpha-benzoyloxydihydro-beta-agarofuran|triptogelin C-1

C28H36O9 (516.2359206)


   

6-O-(3,4-dimethoxybenzoyl)crescentin IV 3-O-beta-D-glucopyranoside

6-O-(3,4-dimethoxybenzoyl)crescentin IV 3-O-beta-D-glucopyranoside

C24H36O12 (516.2206656000001)


   
   

10-methoxy-N(1)-methylburnamine-17-O-benzoate|10-methoxy-N1-methylburnamine-17-O-benzoate

10-methoxy-N(1)-methylburnamine-17-O-benzoate|10-methoxy-N1-methylburnamine-17-O-benzoate

C30H32N2O6 (516.2260252)


   
   

schinarisanlactone A

schinarisanlactone A

C28H36O9 (516.2359206)


   
   
   

C28H36O9_(1R,2R,4S,16R,17R,20S)-13,20-Dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0~1,17~.0~4,16~.0~6,14~.0~8,12~]tricosa-6(14),7,12-trien-2-yl acetate

NCGC00384842-01_C28H36O9_(1R,2R,4S,16R,17R,20S)-13,20-Dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0~1,17~.0~4,16~.0~6,14~.0~8,12~]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359206)


   

(1R,2R,4S,16R,17R,20S)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-2-yl acetate

(1R,2R,4S,16R,17R,20S)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹⁷.0⁴,¹⁶.0⁶,¹⁴.0⁸,¹²]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359206)


   

(1R,2R,4S,16R,17R,20S)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹?.0?,¹?.0?,¹?.0?,¹²]tricosa-6(14),7,12-trien-2-yl acetate

(1R,2R,4S,16R,17R,20S)-13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0¹,¹?.0?,¹?.0?,¹?.0?,¹²]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359206)


   

Ala Thr Tyr Tyr

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-aminopropanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Ala Tyr Thr Tyr

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Ala Tyr Tyr Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-aminopropanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Cys Phe Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H32N4O6S (516.2042452)


   

Cys Phe Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Cys Thr Phe Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2R)-2-amino-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Asp Phe His Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

C24H32N6O7 (516.2332362)


   

Asp Phe Val His

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}-2-phenylethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Asp His Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carboxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C24H32N6O7 (516.2332362)


   

Asp His Val Phe

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}-2-methylpropyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Asp Val Phe His

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-phenylethyl]carbamoyl}-2-methylpropyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Asp Val His Phe

(3S)-3-amino-3-{[(1S)-1-{[(1S)-1-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Glu Ile Gln Gln

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-carboxybutanamido]-3-methylpentanamido]-4-carbamoylbutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Glu Leu Gln Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-4-methylpentanamido]-4-carbamoylbutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Glu Gln Ile Gln

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-4-carbamoylbutanamido]-3-methylpentanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Glu Gln Leu Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-4-carbamoylbutanamido]-4-methylpentanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Glu Gln Gln Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-4-carbamoylbutanamido]-4-carbamoylbutanamido]-3-methylpentanoic acid

C21H36N6O9 (516.2543646)


   

Glu Gln Gln Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carboxybutanamido]-4-carbamoylbutanamido]-4-carbamoylbutanamido]-4-methylpentanoic acid

C21H36N6O9 (516.2543646)


   

Phe Cys Phe Thr

(2S,3R)-2-[(2S)-2-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H32N4O6S (516.2042452)


   

Phe Cys Thr Phe

(2S)-2-[(2S,3R)-2-[(2R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-sulfanylpropanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Phe Asp His Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-carboxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

C24H32N6O7 (516.2332362)


   

Phe Asp Val His

(3S)-3-[(2S)-2-amino-3-phenylpropanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-methylpropyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Phe Phe Cys Thr

(2S,3R)-2-[(2R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanamido]-3-hydroxybutanoic acid

C25H32N4O6S (516.2042452)


   

Phe Phe Phe Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-phenylpropanamido]acetic acid

C29H32N4O5 (516.2372581999999)


   

Phe Phe Gly Phe

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]acetamido}-3-phenylpropanoic acid

C29H32N4O5 (516.2372581999999)


   

Phe Phe Thr Cys

(2R)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-sulfanylpropanoic acid

C25H32N4O6S (516.2042452)


   

Phe Gly Phe Phe

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-3-phenylpropanamido]-3-phenylpropanoic acid

C29H32N4O5 (516.2372581999999)


   

Phe Gly Met Tyr

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O6S (516.2042452)


   

Phe Gly Tyr Met

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-phenylpropanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanoic acid

C25H32N4O6S (516.2042452)


   

Phe His Asp Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-carboxypropanamido]-3-methylbutanoic acid

C24H32N6O7 (516.2332362)


   

Phe His Val Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]butanedioic acid

C24H32N6O7 (516.2332362)


   

Phe Met Gly Tyr

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O6S (516.2042452)


   

Phe Met Tyr Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanamido]acetic acid

C25H32N4O6S (516.2042452)


   

Phe Ser Thr Tyr

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Phe Ser Tyr Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Phe Thr Cys Phe

(2S)-2-[(2R)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Phe Thr Phe Cys

(2R)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-sulfanylpropanoic acid

C25H32N4O6S (516.2042452)


   

Phe Thr Ser Tyr

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Phe Thr Tyr Ser

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-phenylpropanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanoic acid

C25H32N4O8 (516.2220032)


   

Phe Val Asp His

(3S)-3-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Phe Val His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C24H32N6O7 (516.2332362)


   

Phe Tyr Gly Met

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-4-(methylsulfanyl)butanoic acid

C25H32N4O6S (516.2042452)


   

Phe Tyr Met Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanamido]acetic acid

C25H32N4O6S (516.2042452)


   

Phe Tyr Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Phe Tyr Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

C25H32N4O8 (516.2220032)


   

Gly Phe Phe Phe

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C29H32N4O5 (516.2372581999999)


   

Gly Phe Met Tyr

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O6S (516.2042452)


   

Gly Phe Tyr Met

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanoic acid

C25H32N4O6S (516.2042452)


   

Gly Met Phe Tyr

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-(methylsulfanyl)butanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O6S (516.2042452)


   

Gly Met Tyr Phe

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Gly Tyr Phe Met

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-4-(methylsulfanyl)butanoic acid

C25H32N4O6S (516.2042452)


   

Gly Tyr Met Phe

(2S)-2-[(2S)-2-[(2S)-2-(2-aminoacetamido)-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

His Asp Phe Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-carboxypropanamido]-3-phenylpropanamido]-3-methylbutanoic acid

C24H32N6O7 (516.2332362)


   

His Asp Val Phe

(3S)-3-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}-2-methylpropyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

His Phe Asp Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-carboxypropanamido]-3-methylbutanoic acid

C24H32N6O7 (516.2332362)


   

His Phe Val Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]-3-methylbutanamido]butanedioic acid

C24H32N6O7 (516.2332362)


   

His His His Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanoic acid

C21H28N10O6 (516.2193188000001)


   

His His Ser His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H28N10O6 (516.2193188000001)


   

His Met Met Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanoic acid

C21H36N6O5S2 (516.2188486)


   

His Met Val Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanoic acid

C21H36N6O5S2 (516.2188486)


   

His Pro Thr Tyr

(2S)-2-[(2S,3R)-2-{[(2S)-1-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoic acid

C24H32N6O7 (516.2332362)


   

His Pro Tyr Thr

(2S,3R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

His Ser His His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H28N10O6 (516.2193188000001)


   

His Thr Pro Tyr

(2S)-2-{[(2S)-1-[(2S,3R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanoic acid

C24H32N6O7 (516.2332362)


   

His Thr Tyr Pro

(2S)-1-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

His Val Asp Phe

(3S)-3-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-3-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

His Val Phe Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-3-phenylpropanamido]butanedioic acid

C24H32N6O7 (516.2332362)


   

His Val Met Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanoic acid

C21H36N6O5S2 (516.2188486)


   

His Tyr Pro Thr

(2S,3R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

His Tyr Thr Pro

(2S)-1-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Ile Glu Gln Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-carboxybutanamido]-4-carbamoylbutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Ile Gln Glu Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-carbamoylbutanamido]-4-carboxybutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Ile Gln Gln Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3S)-2-amino-3-methylpentanamido]-4-carbamoylbutanamido]-4-carbamoylbutanamido]pentanedioic acid

C21H36N6O9 (516.2543646)


   

Leu Glu Gln Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-carboxybutanamido]-4-carbamoylbutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Perindoprilat glucuronide

Perindoprilat glucuronide

C23H36N2O11 (516.2318986)


   

Leu Gln Glu Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-carbamoylbutanamido]-4-carboxybutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Leu Gln Gln Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-methylpentanamido]-4-carbamoylbutanamido]-4-carbamoylbutanamido]pentanedioic acid

C21H36N6O9 (516.2543646)


   

Met Phe Gly Tyr

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-phenylpropanamido]acetamido}-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O6S (516.2042452)


   

Met Phe Tyr Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]acetic acid

C25H32N4O6S (516.2042452)


   

Met Gly Phe Tyr

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]acetamido}-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O6S (516.2042452)


   

Met Gly Tyr Phe

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]acetamido}-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Met His Met Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-imidazol-4-yl)propanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanoic acid

C21H36N6O5S2 (516.2188486)


   

Met His Val Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanoic acid

C21H36N6O5S2 (516.2188486)


   

Met Met His Val

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-3-(1H-imidazol-4-yl)propanamido]-3-methylbutanoic acid

C21H36N6O5S2 (516.2188486)


   

Met Met Val His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N6O5S2 (516.2188486)


   

Met Asn Pro Arg

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

C20H36N8O6S (516.2478396)


   

Met Asn Arg Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-carbamoylpropanamido]-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

C20H36N8O6S (516.2478396)


   

Met Pro Asn Arg

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-4-(methylsulfanyl)butanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]-5-carbamimidamidopentanoic acid

C20H36N8O6S (516.2478396)


   

Met Pro Arg Asn

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-4-(methylsulfanyl)butanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanamido]-3-carbamoylpropanoic acid

C20H36N8O6S (516.2478396)


   

Met Arg Asn Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C20H36N8O6S (516.2478396)


   

Met Arg Pro Asn

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C20H36N8O6S (516.2478396)


   

Met Val His Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C21H36N6O5S2 (516.2188486)


   

Met Val Met His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-methylbutanamido]-4-(methylsulfanyl)butanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N6O5S2 (516.2188486)


   

Met Tyr Phe Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetic acid

C25H32N4O6S (516.2042452)


   

Met Tyr Gly Phe

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-4-(methylsulfanyl)butanamido]-3-(4-hydroxyphenyl)propanamido]acetamido}-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Asn Met Pro Arg

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-4-(methylsulfanyl)butanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanoic acid

C20H36N8O6S (516.2478396)


   

Asn Met Arg Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanoyl]pyrrolidine-2-carboxylic acid

C20H36N8O6S (516.2478396)


   

Asn Asn Asn Arg

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-carbamoylpropanamido]-3-carbamoylpropanamido]-5-carbamimidamidopentanoic acid

C18H32N10O8 (516.2404472000001)


   

Asn Asn Arg Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-carbamoylpropanamido]-5-carbamimidamidopentanamido]-3-carbamoylpropanoic acid

C18H32N10O8 (516.2404472000001)


   

Asn Pro Met Arg

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-4-(methylsulfanyl)butanamido]-5-carbamimidamidopentanoic acid

C20H36N8O6S (516.2478396)


   

Asn Pro Arg Met

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanoic acid

C20H36N8O6S (516.2478396)


   

Asn Pro Thr Trp

(2S)-2-[(2S,3R)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Asn Pro Trp Thr

(2S,3R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Asn Gln Gln Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-4-carbamoylbutanamido]-4-carbamoylbutanamido]-4-carbamoylbutanoic acid

C19H32N8O9 (516.2292142)


   

Asn Arg Met Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanoyl]pyrrolidine-2-carboxylic acid

C20H36N8O6S (516.2478396)


   

Asn Arg Asn Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-5-carbamimidamidopentanamido]-3-carbamoylpropanamido]-3-carbamoylpropanoic acid

C18H32N10O8 (516.2404472000001)


   

Asn Arg Pro Met

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-4-(methylsulfanyl)butanoic acid

C20H36N8O6S (516.2478396)


   

Asn Thr Pro Trp

(2S)-2-{[(2S)-1-[(2S,3R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Asn Thr Trp Pro

(2S)-1-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Asn Trp Pro Thr

(2S,3R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Asn Trp Thr Pro

(2S)-1-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Pro His Thr Tyr

(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-3-(1H-imidazol-4-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]butanamido]-3-(4-hydroxyphenyl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro His Tyr Thr

(2S,3R)-3-hydroxy-2-[(2S)-3-(4-hydroxyphenyl)-2-[(2S)-3-(1H-imidazol-4-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]butanoic acid

C24H32N6O7 (516.2332362)


   

Pro Met Asn Arg

(2S)-5-carbamimidamido-2-[(2S)-3-carbamoyl-2-[(2S)-4-(methylsulfanyl)-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]propanamido]pentanoic acid

C20H36N8O6S (516.2478396)


   

Pro Met Arg Asn

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-4-(methylsulfanyl)-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]pentanamido]-3-carbamoylpropanoic acid

C20H36N8O6S (516.2478396)


   

Pro Asn Met Arg

(2S)-5-carbamimidamido-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-4-(methylsulfanyl)butanamido]pentanoic acid

C20H36N8O6S (516.2478396)


   

Pro Asn Arg Met

(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]pentanamido]-4-(methylsulfanyl)butanoic acid

C20H36N8O6S (516.2478396)


   

Pro Asn Thr Trp

(2S)-2-[(2S,3R)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Asn Trp Thr

(2S,3R)-2-[(2S)-2-[(2S)-3-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Pro Gln Ser Trp

(2S)-2-[(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Gln Trp Ser

(2S)-2-[(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C24H32N6O7 (516.2332362)


   

Pro Arg Met Asn

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]-4-(methylsulfanyl)butanamido]-3-carbamoylpropanoic acid

C20H36N8O6S (516.2478396)


   

Pro Arg Asn Met

(2S)-2-[(2S)-2-[(2S)-5-carbamimidamido-2-[(2S)-pyrrolidin-2-ylformamido]pentanamido]-3-carbamoylpropanamido]-4-(methylsulfanyl)butanoic acid

C20H36N8O6S (516.2478396)


   

Pro Ser Gln Trp

(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]butanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Ser Trp Gln

(2S)-4-carbamoyl-2-[(2S)-2-[(2S)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-(1H-indol-3-yl)propanamido]butanoic acid

C24H32N6O7 (516.2332362)


   

Pro Thr His Tyr

(2S)-2-[(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Thr Asn Trp

(2S)-2-[(2S)-3-carbamoyl-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]propanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Thr Trp Asn

(2S)-3-carbamoyl-2-[(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-3-(1H-indol-3-yl)propanamido]propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Thr Tyr His

(2S)-2-[(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-pyrrolidin-2-ylformamido]butanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Trp Asn Thr

(2S,3R)-2-[(2S)-3-carbamoyl-2-[(2S)-3-(1H-indol-3-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Pro Trp Gln Ser

(2S)-2-[(2S)-4-carbamoyl-2-[(2S)-3-(1H-indol-3-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]butanamido]-3-hydroxypropanoic acid

C24H32N6O7 (516.2332362)


   

Pro Trp Ser Gln

(2S)-4-carbamoyl-2-[(2S)-3-hydroxy-2-[(2S)-3-(1H-indol-3-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]propanamido]butanoic acid

C24H32N6O7 (516.2332362)


   

Pro Trp Thr Asn

(2S)-3-carbamoyl-2-[(2S,3R)-3-hydroxy-2-[(2S)-3-(1H-indol-3-yl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]butanamido]propanoic acid

C24H32N6O7 (516.2332362)


   

Pro Tyr His Thr

(2S,3R)-3-hydroxy-2-[(2S)-2-[(2S)-3-(4-hydroxyphenyl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]-3-(1H-imidazol-4-yl)propanamido]butanoic acid

C24H32N6O7 (516.2332362)


   

Pro Tyr Thr His

(2S)-2-[(2S,3R)-3-hydroxy-2-[(2S)-3-(4-hydroxyphenyl)-2-[(2S)-pyrrolidin-2-ylformamido]propanamido]butanamido]-3-(1H-imidazol-4-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Gln Glu Ile Gln

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carboxybutanamido]-3-methylpentanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Gln Glu Leu Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carboxybutanamido]-4-methylpentanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Gln Glu Gln Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carboxybutanamido]-4-carbamoylbutanamido]-3-methylpentanoic acid

C21H36N6O9 (516.2543646)


   

Gln Glu Gln Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carboxybutanamido]-4-carbamoylbutanamido]-4-methylpentanoic acid

C21H36N6O9 (516.2543646)


   

Gln Ile Glu Gln

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-methylpentanamido]-4-carboxybutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Gln Ile Gln Glu

(2S)-2-[(2S)-2-[(2S,3S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-methylpentanamido]-4-carbamoylbutanamido]pentanedioic acid

C21H36N6O9 (516.2543646)


   

Gln Leu Glu Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-methylpentanamido]-4-carboxybutanamido]-4-carbamoylbutanoic acid

C21H36N6O9 (516.2543646)


   

Gln Leu Gln Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-methylpentanamido]-4-carbamoylbutanamido]pentanedioic acid

C21H36N6O9 (516.2543646)


   

Gln Asn Gln Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-carbamoylpropanamido]-4-carbamoylbutanamido]-4-carbamoylbutanoic acid

C19H32N8O9 (516.2292142)


   

Gln Pro Ser Trp

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Gln Pro Trp Ser

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoic acid

C24H32N6O7 (516.2332362)


   

Gln Gln Glu Ile

(2S,3S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carbamoylbutanamido]-4-carboxybutanamido]-3-methylpentanoic acid

C21H36N6O9 (516.2543646)


   

Gln Gln Glu Leu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carbamoylbutanamido]-4-carboxybutanamido]-4-methylpentanoic acid

C21H36N6O9 (516.2543646)


   

Gln Gln Ile Glu

(2S)-2-[(2S,3S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carbamoylbutanamido]-3-methylpentanamido]pentanedioic acid

C21H36N6O9 (516.2543646)


   

Gln Gln Leu Glu

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carbamoylbutanamido]-4-methylpentanamido]pentanedioic acid

C21H36N6O9 (516.2543646)


   

Gln Gln Asn Gln

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carbamoylbutanamido]-3-carbamoylpropanamido]-4-carbamoylbutanoic acid

C19H32N8O9 (516.2292142)


   

Gln Gln Gln Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-4-carbamoylbutanamido]-4-carbamoylbutanamido]-3-carbamoylpropanoic acid

C19H32N8O9 (516.2292142)


   

Gln Ser Pro Trp

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Gln Ser Trp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Gln Trp Pro Ser

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanoic acid

C24H32N6O7 (516.2332362)


   

Gln Trp Ser Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Arg Met Asn Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C20H36N8O6S (516.2478396)


   

Arg Met Pro Asn

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-4-(methylsulfanyl)butanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C20H36N8O6S (516.2478396)


   

Arg Asn Met Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-carbamoylpropanamido]-4-(methylsulfanyl)butanoyl]pyrrolidine-2-carboxylic acid

C20H36N8O6S (516.2478396)


   

Arg Asn Asn Asn

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-carbamoylpropanamido]-3-carbamoylpropanamido]-3-carbamoylpropanoic acid

C18H32N10O8 (516.2404472000001)


   

Arg Asn Pro Met

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-5-carbamimidamidopentanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-4-(methylsulfanyl)butanoic acid

C20H36N8O6S (516.2478396)


   

Arg Pro Met Asn

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-4-(methylsulfanyl)butanamido]-3-carbamoylpropanoic acid

C20H36N8O6S (516.2478396)


   

Arg Pro Asn Met

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-5-carbamimidamidopentanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]-4-(methylsulfanyl)butanoic acid

C20H36N8O6S (516.2478396)


   

Ser Phe Thr Tyr

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Ser Phe Tyr Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Ser His His His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H28N10O6 (516.2193188000001)


   

Ser Pro Gln Trp

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Ser Pro Trp Gln

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoic acid

C24H32N6O7 (516.2332362)


   

Ser Gln Pro Trp

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Ser Gln Trp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-4-carbamoylbutanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Ser Thr Phe Tyr

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Ser Thr Tyr Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanoic acid

C25H32N4O8 (516.2220032)


   

Ser Trp Pro Gln

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanoic acid

C24H32N6O7 (516.2332362)


   

Ser Trp Gln Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Ser Tyr Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Ser Tyr Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H32N4O8 (516.2220032)


   

Thr Ala Tyr Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Thr Cys Phe Phe

(2S)-2-[(2S)-2-[(2R)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-sulfanylpropanamido]-3-phenylpropanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Thr Phe Cys Phe

(2S)-2-[(2R)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-sulfanylpropanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Thr Phe Phe Cys

(2R)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-phenylpropanamido]-3-sulfanylpropanoic acid

C25H32N4O6S (516.2042452)


   

Thr Phe Ser Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Thr Phe Tyr Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanoic acid

C25H32N4O8 (516.2220032)


   

Thr His Pro Tyr

(2S)-2-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanoic acid

C24H32N6O7 (516.2332362)


   

Thr His Tyr Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Thr Asn Pro Trp

(2S)-2-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Thr Asn Trp Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Thr Pro His Tyr

(2S)-2-[(2S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-(1H-imidazol-4-yl)propanamido]-3-(4-hydroxyphenyl)propanoic acid

C24H32N6O7 (516.2332362)


   

Thr Pro Asn Trp

(2S)-2-[(2S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]-3-(1H-indol-3-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Thr Pro Trp Asn

(2S)-2-[(2S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanoic acid

C24H32N6O7 (516.2332362)


   

Thr Pro Tyr His

(2S)-2-[(2S)-2-{[(2S)-1-[(2S,3R)-2-amino-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Thr Ser Phe Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-phenylpropanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Thr Ser Tyr Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-hydroxypropanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanoic acid

C25H32N4O8 (516.2220032)


   

Thr Trp Asn Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Thr Trp Pro Asn

(2S)-2-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C24H32N6O7 (516.2332362)


   

Thr Tyr Ala Tyr

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Thr Tyr Phe Ser

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-hydroxypropanoic acid

C25H32N4O8 (516.2220032)


   

Thr Tyr His Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Thr Tyr Pro His

(2S)-2-{[(2S)-1-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-(1H-imidazol-4-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Thr Tyr Ser Phe

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-phenylpropanoic acid

C25H32N4O8 (516.2220032)


   

Thr Tyr Tyr Ala

(2S)-2-[(2S)-2-[(2S)-2-[(2S,3R)-2-amino-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]propanoic acid

C25H32N4O8 (516.2220032)


   

Val Asp Phe His

(3S)-3-[(2S)-2-amino-3-methylbutanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}-2-phenylethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Val Asp His Phe

(3S)-3-[(2S)-2-amino-3-methylbutanamido]-3-{[(1S)-1-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Val Phe Asp His

(3S)-3-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]-3-{[(1S)-1-carboxy-2-(1H-imidazol-4-yl)ethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Val Phe His Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-phenylpropanamido]-3-(1H-imidazol-4-yl)propanamido]butanedioic acid

C24H32N6O7 (516.2332362)


   

Val His Asp Phe

(3S)-3-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-{[(1S)-1-carboxy-2-phenylethyl]carbamoyl}propanoic acid

C24H32N6O7 (516.2332362)


   

Val His Phe Asp

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-3-phenylpropanamido]butanedioic acid

C24H32N6O7 (516.2332362)


   

Val His Met Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-3-(1H-imidazol-4-yl)propanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanoic acid

C21H36N6O5S2 (516.2188486)


   

Val Met His Met

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-(methylsulfanyl)butanamido]-3-(1H-imidazol-4-yl)propanamido]-4-(methylsulfanyl)butanoic acid

C21H36N6O5S2 (516.2188486)


   

Val Met Met His

(2S)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-methylbutanamido]-4-(methylsulfanyl)butanamido]-4-(methylsulfanyl)butanamido]-3-(1H-imidazol-4-yl)propanoic acid

C21H36N6O5S2 (516.2188486)


   

Trp Asn Pro Thr

(2S,3R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Trp Asn Thr Pro

(2S)-1-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-carbamoylpropanamido]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Trp Pro Asn Thr

(2S,3R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanamido]-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Trp Pro Gln Ser

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanamido]-3-hydroxypropanoic acid

C24H32N6O7 (516.2332362)


   

Trp Pro Ser Gln

(2S)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanamido]-4-carbamoylbutanoic acid

C24H32N6O7 (516.2332362)


   

Trp Pro Thr Asn

(2S)-2-[(2S,3R)-2-{[(2S)-1-[(2S)-2-amino-3-(1H-indol-3-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanamido]-3-carbamoylpropanoic acid

C24H32N6O7 (516.2332362)


   

Trp Gln Pro Ser

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanoyl]pyrrolidin-2-yl]formamido}-3-hydroxypropanoic acid

C24H32N6O7 (516.2332362)


   

Trp Gln Ser Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-4-carbamoylbutanamido]-3-hydroxypropanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Trp Ser Pro Gln

(2S)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanoyl]pyrrolidin-2-yl]formamido}-4-carbamoylbutanoic acid

C24H32N6O7 (516.2332362)


   

Trp Ser Gln Pro

(2S)-1-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxypropanamido]-4-carbamoylbutanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Trp Thr Asn Pro

(2S)-1-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanamido]-3-carbamoylpropanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Trp Thr Pro Asn

(2S)-2-{[(2S)-1-[(2S,3R)-2-[(2S)-2-amino-3-(1H-indol-3-yl)propanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-carbamoylpropanoic acid

C24H32N6O7 (516.2332362)


   

Tyr Ala Thr Tyr

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Ala Tyr Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]propanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Phe Gly Met

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]acetamido}-4-(methylsulfanyl)butanoic acid

C25H32N4O6S (516.2042452)


   

Tyr Phe Met Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-4-(methylsulfanyl)butanamido]acetic acid

C25H32N4O6S (516.2042452)


   

Tyr Phe Ser Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-hydroxypropanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Phe Thr Ser

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-phenylpropanamido]-3-hydroxybutanamido]-3-hydroxypropanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Gly Met Phe

(2S)-2-[(2S)-2-{2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]acetamido}-4-(methylsulfanyl)butanamido]-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Tyr His Pro Thr

(2S,3R)-2-{[(2S)-1-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Tyr His Thr Pro

(2S)-1-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Tyr Met Phe Gly

2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanamido]-3-phenylpropanamido]acetic acid

C25H32N4O6S (516.2042452)


   

Tyr Met Gly Phe

(2S)-2-{2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-4-(methylsulfanyl)butanamido]acetamido}-3-phenylpropanoic acid

C25H32N4O6S (516.2042452)


   

Tyr Pro His Thr

(2S,3R)-2-[(2S)-2-{[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-(1H-imidazol-4-yl)propanamido]-3-hydroxybutanoic acid

C24H32N6O7 (516.2332362)


   

Tyr Pro Thr His

(2S)-2-[(2S,3R)-2-{[(2S)-1-[(2S)-2-amino-3-(4-hydroxyphenyl)propanoyl]pyrrolidin-2-yl]formamido}-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Tyr Ser Phe Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-phenylpropanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Ser Thr Phe

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxypropanamido]-3-hydroxybutanamido]-3-phenylpropanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Thr Ala Tyr

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]propanamido]-3-(4-hydroxyphenyl)propanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Thr Phe Ser

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-phenylpropanamido]-3-hydroxypropanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Thr His Pro

(2S)-1-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-(1H-imidazol-4-yl)propanoyl]pyrrolidine-2-carboxylic acid

C24H32N6O7 (516.2332362)


   

Tyr Thr Pro His

(2S)-2-{[(2S)-1-[(2S,3R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanoyl]pyrrolidin-2-yl]formamido}-3-(1H-imidazol-4-yl)propanoic acid

C24H32N6O7 (516.2332362)


   

Tyr Thr Ser Phe

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-hydroxypropanamido]-3-phenylpropanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Thr Tyr Ala

(2S)-2-[(2S)-2-[(2S,3R)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]-3-(4-hydroxyphenyl)propanamido]propanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Tyr Ala Thr

(2S,3R)-2-[(2S)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]propanamido]-3-hydroxybutanoic acid

C25H32N4O8 (516.2220032)


   

Tyr Tyr Thr Ala

(2S)-2-[(2S,3R)-2-[(2S)-2-[(2S)-2-amino-3-(4-hydroxyphenyl)propanamido]-3-(4-hydroxyphenyl)propanamido]-3-hydroxybutanamido]propanoic acid

C25H32N4O8 (516.2220032)


   

PDAKS

Pro-Asp-Ala-Lys-Ser

C21H36N6O9 (516.2543646)


   

13,14-epoxy Fluprostenol Isopropyl Ester

9α,11α,15R-trihydroxy-16-(3-trifluoromethyl)-13,14-epoxy-17,18,19,20-tetranor-prosta-5Z,13E-dien-1-oic-acid, isopropyl ester

C26H35F3O7 (516.2334756)


   

Idebenone Metabolite (β-D-Glucopyranosiduronic acid, 4-hydroxy-3-(10-hydroxydecyl)-5,6-dimethoxy-

Idebenone Metabolite (β-D-Glucopyranosiduronic acid, 4-hydroxy-3-(10-hydroxydecyl)-5,6-dimethoxy-

C25H40O11 (516.257049)


   

PI(12:0/0:0)

1-dodecanoyl-glycero-3-phospho-(1-myo-inositol)

C21H41O12P (516.2335516)


   

Udenafil

3-{1-methyl-7-oxo-3-propyl-1H,4H,7H-pyrazolo[4,3-d]pyrimidin-5-yl}-N-[2-(1-methylpyrrolidin-2-yl)ethyl]-4-propoxybenzene-1-sulfonamide

C25H36N6O4S (516.2518616)


G - Genito urinary system and sex hormones > G04 - Urologicals > G04B - Urologicals > G04BE - Drugs used in erectile dysfunction D004791 - Enzyme Inhibitors > D010726 - Phosphodiesterase Inhibitors > D058986 - Phosphodiesterase 5 Inhibitors C471 - Enzyme Inhibitor > C744 - Phosphodiesterase Inhibitor > C2127 - cGMP Phosphodiesterase Inhibitor

   

Austalide A

13,20-dimethoxy-4,7,17,22,22-pentamethyl-11-oxo-5,10,21,23-tetraoxahexacyclo[18.2.1.0^{1,17}.0^{4,16}.0^{6,14}.0^{8,12}]tricosa-6(14),7,12-trien-2-yl acetate

C28H36O9 (516.2359206)


   

Eriojaposide B

3,5,5-trimethyl-4-[(1E)-3-[(3,4,5-trihydroxy-6-{[(3,4,5-trihydroxy-6-methyloxan-2-yl)oxy]methyl}oxan-2-yl)oxy]but-1-en-1-yl]cyclohex-2-en-1-one

C25H40O11 (516.257049)


D020011 - Protective Agents > D000975 - Antioxidants > D002338 - Carotenoids

   

13(S),14(S)-epoxy Fluprostenol isopropyl ester

13(S),14(S)-epoxy Fluprostenol isopropyl ester

C26H35F3O7 (516.2334756)


   

LPI 12:0

1-dodecanoyl-glycero-3-phospho-(1-myo-inositol)

C21H41O12P (516.2335516)


   

ST 28:7;O9

(1beta,3beta,5beta)-1,3,5-[(1R)-ethylidynetris(oxy)]-2,14beta-dihydroxy-19beta-acetoxy-bufa-20,22-dienolide

C28H36O9 (516.2359206)


   

N,N-Bis(3-methylphenyl)-N,N-diphenyl-4,4-biphenyldiamine

N,N-Bis(3-methylphenyl)-N,N-diphenyl-4,4-biphenyldiamine

C38H32N2 (516.2565352)


   

Boc-Ala-Glu-Val-Asp-aldehyde (pseudo acid)

Boc-Ala-Glu-Val-Asp-aldehyde (pseudo acid)

C22H36N4O10 (516.2431316)


   

1-(Perfluoro-n-hexyl)tetradecane

1-(Perfluoro-n-hexyl)tetradecane

C20H29F13 (516.206155)


   

N,N-Diphenyl-N,N-di(p-tolyl)benzidine

N,N-Diphenyl-N,N-di(p-tolyl)benzidine

C38H32N2 (516.2565352)


   

fmoc-d-4-aminomethylphenylalanine(boc)

fmoc-d-4-aminomethylphenylalanine(boc)

C30H32N2O6 (516.2260252)


   

3,3-(1,4-Phenylenedi-2,1-ethenediyl)bis(9-ethyl-9H-carbazole)

3,3-(1,4-Phenylenedi-2,1-ethenediyl)bis(9-ethyl-9H-carbazole)

C38H32N2 (516.2565352)


   

europium(3+),1,2,3,5-tetramethylcyclopenta-1,3-diene

europium(3+),1,2,3,5-tetramethylcyclopenta-1,3-diene

C27H39Eu (516.2264024)


   

boc-l-4-aminomethylphenylalanine(fmoc)

boc-l-4-aminomethylphenylalanine(fmoc)

C30H32N2O6 (516.2260252)


   

2-[(e)-3-(3,3-dimethyl-1-phenyl-1,3-dihydro-2h-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-1-phenyl-3h-indolium chloride

2-[(e)-3-(3,3-dimethyl-1-phenyl-1,3-dihydro-2h-indol-2-ylidene)-1-propenyl]-3,3-dimethyl-1-phenyl-3h-indolium chloride

C35H33ClN2 (516.2332128)


   

2-acetamido-3,4,6-tri-o-benzyl-2-deoxy-beta-d-glucopyranosyl azide

2-acetamido-3,4,6-tri-o-benzyl-2-deoxy-beta-d-glucopyranosyl azide

C29H32N4O5 (516.2372581999999)


   

BATES REAGENT MU-OXO-BIS[TRIS(DIMETHYLAMINO)PHOSPHONIUM]BIS(TETRAFLUOROBORATE)

BATES REAGENT MU-OXO-BIS[TRIS(DIMETHYLAMINO)PHOSPHONIUM]BIS(TETRAFLUOROBORATE)

C12H36B2F8N6OP2 (516.2484062)


   

Boc-D-4-Aminomethylphe(Fmoc)

Boc-D-4-Aminomethylphe(Fmoc)

C30H32N2O6 (516.2260252)


   

fmoc-d, l-phe(4-ch2nh-boc)

fmoc-d, l-phe(4-ch2nh-boc)

C30H32N2O6 (516.2260252)


   

MCOPPB trihydrochloride

MCOPPB trihydrochloride

C26H43Cl3N4 (516.2553128000001)


MCOPPB trihydrochloride is a nociceptin receptor agonist with pKi of 10.07; weaker activity at other opioid receptors. IC50 value: 10.07 (pKi) Target: nociceptin receptor MCOPPB trihydrochloride is a trihydrochloride form of MCOPPB that is a new nonpeptide nociceptin/orphanin FQ peptide (NOP)-receptor agonist with a pKi of 10.07 ± 0.01 for the human NOP receptor.

   

N,N-Bis(3-methylphenyl)-N,N-bis(phenyl)benzidine

N,N-Bis(3-methylphenyl)-N,N-bis(phenyl)benzidine

C38H32N2 (516.2565352)


   

Hesperadin

Hesperadin

C29H32N4O3S (516.2195002)


D004791 - Enzyme Inhibitors > D047428 - Protein Kinase Inhibitors

   

Siponimod

Siponimod

C29H35F3N2O3 (516.2599636)


L - Antineoplastic and immunomodulating agents > L04 - Immunosuppressants > L04A - Immunosuppressants > L04AA - Selective immunosuppressants D007155 - Immunologic Factors > D007166 - Immunosuppressive Agents > D000081243 - Sphingosine 1 Phosphate Receptor Modulators C308 - Immunotherapeutic Agent

   

D-glycero-D-gulo-Dec-1-enitol, 4,7-anhydro-1,2,3,8-tetradeoxy-6-O-(phenylmethyl)-, 9,10-dibenzoate

D-glycero-D-gulo-Dec-1-enitol, 4,7-anhydro-1,2,3,8-tetradeoxy-6-O-(phenylmethyl)-, 9,10-dibenzoate

C31H32O7 (516.2147921999999)


   

alpha-[butylamino]methyl-p-hydroxybenzyl alcohol

alpha-[butylamino]methyl-p-hydroxybenzyl alcohol

C24H40N2O8S (516.250524)


   

3-ethenyl-4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-ylmethyl)-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

3-ethenyl-4-(2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-ylmethyl)-2-[3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

C26H32N2O9 (516.2107702)


   

(3alphaS,21S)-strictosidinate

(3alphaS,21S)-strictosidinate

C26H32N2O9 (516.2107702)


   

(3alphaS,21R)-strictosidinate

(3alphaS,21R)-strictosidinate

C26H32N2O9 (516.2107702)


   

(2S,3R,4S)-3-ethenyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

(2S,3R,4S)-3-ethenyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

C26H32N2O9 (516.2107702)


   

(2R,3R,4S)-3-ethenyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

(2R,3R,4S)-3-ethenyl-4-[[(1S)-2,3,4,9-tetrahydro-1H-pyrido[3,4-b]indol-1-yl]methyl]-2-[(2R,3S,4R,5R,6S)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-3,4-dihydro-2H-pyran-5-carboxylic acid

C26H32N2O9 (516.2107702)


   

PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

PA(2:0/20:4(6E,8Z,11Z,14Z)-OH(5S))

C25H41O9P (516.2488066)


   

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0)

PA(20:4(6E,8Z,11Z,14Z)-OH(5S)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9))

PA(2:0/20:4(5Z,7E,11Z,14Z)-OH(9))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0)

PA(20:4(5Z,7E,11Z,14Z)-OH(9)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S))

PA(2:0/20:3(5Z,8Z,11Z)-O(14R,15S))

C25H41O9P (516.2488066)


   

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0)

PA(20:3(5Z,8Z,11Z)-O(14R,15S)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R))

PA(2:0/20:3(5Z,8Z,14Z)-O(11S,12R))

C25H41O9P (516.2488066)


   

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0)

PA(20:3(5Z,8Z,14Z)-O(11S,12R)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:3(5Z,11Z,14Z)-O(8,9))

PA(2:0/20:3(5Z,11Z,14Z)-O(8,9))

C25H41O9P (516.2488066)


   

PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0)

PA(20:3(5Z,11Z,14Z)-O(8,9)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:3(8Z,11Z,14Z)-O(5,6))

PA(2:0/20:3(8Z,11Z,14Z)-O(5,6))

C25H41O9P (516.2488066)


   

PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0)

PA(20:3(8Z,11Z,14Z)-O(5,6)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(20))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(20)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(19S))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(19S)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(18R))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(18R)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(17))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(17)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

PA(2:0/20:4(5Z,8Z,11Z,14Z)-OH(16R))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0)

PA(20:4(5Z,8Z,11Z,14Z)-OH(16R)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

PA(2:0/20:4(5Z,8Z,11Z,13E)-OH(15S))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0)

PA(20:4(5Z,8Z,11Z,13E)-OH(15S)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

PA(2:0/20:4(5Z,8Z,10E,14Z)-OH(12S))

C25H41O9P (516.2488066)


   

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0)

PA(20:4(5Z,8Z,10E,14Z)-OH(12S)/2:0)

C25H41O9P (516.2488066)


   

PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

PA(2:0/20:4(5E,8Z,12Z,14Z)-OH(11R))

C25H41O9P (516.2488066)


   

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0)

PA(20:4(5E,8Z,12Z,14Z)-OH(11R)/2:0)

C25H41O9P (516.2488066)


   

triptogelin C-1

triptogelin C-1

C28H36O9 (516.2359206)


A natural product found particularly in Celastrus orbiculatus and Tripterygium wilfordii regelii.

   

Gusanlungionoside A

Gusanlungionoside A

C25H40O11 (516.257049)


A natural product found in Arcangelisia gusanlung.

   
   

Gusanlungionoside B

Gusanlungionoside B

C25H40O11 (516.257049)


A natural product found in Arcangelisia gusanlung.

   

alpha-((Butylamino)methyl)-p-hydroxybenzyl alcohol sulfate

alpha-((Butylamino)methyl)-p-hydroxybenzyl alcohol sulfate

C24H40N2O8S (516.250524)


C78272 - Agent Affecting Nervous System > C29747 - Adrenergic Agent > C87053 - Adrenergic Agonist

   
   

2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1S,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

3-(2,5-difluorophenyl)-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

3-(2,5-difluorophenyl)-1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

3-(2,5-difluorophenyl)-1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4S,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2R,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(1S,3S,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

N-[(1S,3S,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

C27H30F2N2O6 (516.2071824)


   

3-(2,5-difluorophenyl)-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

3-(2,5-difluorophenyl)-1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

3-(2,5-difluorophenyl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

3-(2,5-difluorophenyl)-1-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

3-(2,5-difluorophenyl)-1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

3-(2,5-difluorophenyl)-1-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-8-(3-methoxyprop-1-ynyl)-3-methyl-6-oxo-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-1-methylurea

C26H30F2N4O5 (516.2184153999999)


   

N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4R,5R)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4R,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

N-[[(4S,5S)-8-(1-cyclopentenyl)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-4-fluoro-N-methylbenzamide

C27H33FN2O5S (516.20941)


   

N-[(2S,3R,6R)-6-[2-(4-benzylpiperidin-1-yl)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]-4-methoxybenzenesulfonamide

N-[(2S,3R,6R)-6-[2-(4-benzylpiperidin-1-yl)-2-oxoethyl]-2-(hydroxymethyl)oxan-3-yl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2R,3R,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(1R,3R,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide

N-[(1R,3R,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide

C27H30F2N2O6 (516.2071824)


   

N-[(1R,3S,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide

N-[(1R,3S,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide

C27H30F2N2O6 (516.2071824)


   

N-[(1S,3R,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide

N-[(1S,3R,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b][1]benzofuran-6-yl]oxane-4-carboxamide

C27H30F2N2O6 (516.2071824)


   

2-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2R,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

2-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2S,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

2-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2S,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

2-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2R,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

3-cyclopentyl-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

3-cyclopentyl-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

2-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2R,3R)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4R,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4S,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

(2S)-2-[(4S,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2S)-2-[(4S,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2457934)


   

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2R,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2S,3S,6R)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(1S,3S,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

N-[(1S,3S,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

C27H30F2N2O6 (516.2071824)


   

2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1S,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1R,3S,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

3-cyclopentyl-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4S,5S)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

3-cyclopentyl-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

3-cyclopentyl-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

3-cyclopentyl-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4R,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

2-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2S,3S)-5-[(2S)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

2-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2R,3S)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

3-cyclopentyl-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4S,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

2-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

2-fluoro-N-[[(2S,3R)-5-[(2R)-1-hydroxypropan-2-yl]-3-methyl-6-oxo-8-(2-pyridin-4-ylethynyl)-3,4-dihydro-2H-pyrido[2,3-b][1,5]oxazocin-2-yl]methyl]-N-methylbenzamide

C29H29FN4O4 (516.2172726)


   

3-cyclopentyl-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

3-cyclopentyl-1-[[(4S,5S)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(3-pyridinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-1-methylurea

C26H36N4O5S (516.2406286)


   

N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4R,5R)-2-[(2R)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

N-[[(4R,5R)-2-[(2S)-1-hydroxypropan-2-yl]-4-methyl-1,1-dioxo-8-(5-pyrimidinyl)-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-5-yl]methyl]-N-methylcyclohexanecarboxamide

C26H36N4O5S (516.2406286)


   

(2R)-2-[(4S,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4S,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2457934)


   

(2R)-2-[(4R,5R)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4R,5R)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2457934)


   

(2R)-2-[(4R,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2R)-2-[(4R,5S)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2457934)


   

(2S)-2-[(4S,5R)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

(2S)-2-[(4S,5R)-8-(1-cyclohexenyl)-5-[[(2-fluorophenyl)methyl-methylamino]methyl]-4-methyl-1,1-dioxo-4,5-dihydro-3H-6,1$l^{6},2-benzoxathiazocin-2-yl]-1-propanol

C28H37FN2O4S (516.2457934)


   

1-[(5S,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(2-chlorophenyl)urea

1-[(5S,6R,9R)-8-acetyl-5-methoxy-3,6,9-trimethyl-2-oxo-11-oxa-3,8-diazabicyclo[10.4.0]hexadeca-1(12),13,15-trien-14-yl]-3-(2-chlorophenyl)urea

C26H33ClN4O5 (516.2139358000001)


   

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2S,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2S,3S,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

N-[(2R,3R,6S)-2-(hydroxymethyl)-6-[2-oxo-2-[4-(phenylmethyl)-1-piperidinyl]ethyl]-3-oxanyl]-4-methoxybenzenesulfonamide

C27H36N2O6S (516.2293956)


   

N-[(1R,3S,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

N-[(1R,3S,4aR,9aS)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

C27H30F2N2O6 (516.2071824)


   

N-[(1S,3R,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

N-[(1S,3R,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

C27H30F2N2O6 (516.2071824)


   

N-[(1R,3R,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

N-[(1R,3R,4aS,9aR)-3-[2-[(2,5-difluorophenyl)methylamino]-2-oxoethyl]-1-(hydroxymethyl)-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-6-yl]-4-oxanecarboxamide

C27H30F2N2O6 (516.2071824)


   

2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1R,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1R,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1R,3R,4aS,9aR)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1S,3S,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

2-[(1S,3R,4aR,9aS)-1-(hydroxymethyl)-6-[(2-methoxy-1-oxoethyl)amino]-3,4,4a,9a-tetrahydro-1H-pyrano[3,4-b]benzofuran-3-yl]-N-[(4-phenylphenyl)methyl]acetamide

C30H32N2O6 (516.2260252)


   

N,N-bis(2,3-dihydroxybenzoyl)-N-hexanoyltren

N,N-bis(2,3-dihydroxybenzoyl)-N-hexanoyltren

C26H36N4O7 (516.2583866)


   

4-[(4-anilinophenyl)-(4-phenyliminocyclohexa-2,5-dien-1-ylidene)methyl]-N-phenylaniline;hydron

4-[(4-anilinophenyl)-(4-phenyliminocyclohexa-2,5-dien-1-ylidene)methyl]-N-phenylaniline;hydron

C37H30N3+ (516.24396)


   

[2,4-dihydroxy-3-[(E)-3-methylbut-1-enyl]phenyl]-[6-(2,4-dihydroxyphenyl)-2-(2,6-dihydroxyphenyl)-4-methylcyclohex-3-en-1-yl]methanone

[2,4-dihydroxy-3-[(E)-3-methylbut-1-enyl]phenyl]-[6-(2,4-dihydroxyphenyl)-2-(2,6-dihydroxyphenyl)-4-methylcyclohex-3-en-1-yl]methanone

C31H32O7 (516.2147921999999)


   
   
   

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] dodecanoate

[2-Hydroxy-3-[hydroxy-(2,3,4,5,6-pentahydroxycyclohexyl)oxyphosphoryl]oxypropyl] dodecanoate

C21H41O12P (516.2335516)


   
   

N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

N-(3-aminopropyl)-N-[1-(3-benzyl-7-chloro-4-oxoquinazolin-2-yl)-2-methylpropyl]-4-methylbenzamide

C30H33ClN4O2 (516.2291908000001)


   

1-dodecanoyl-glycero-3-phospho-(1-myo-inositol)

1-dodecanoyl-glycero-3-phospho-(1-myo-inositol)

C21H41O12P (516.2335516)


   

Ejap-2

Ejap-2

C28H36O9 (516.2359206)


A natural product found in Celastrus orbiculatus and Euonymus japonicus.

   
   
   
   
   
   
   
   
   
   
   
   
   
   
   
   

BI-2852

BI-2852

C31H28N6O2 (516.2273628)


BI-2852 is a KRAS inhibitor for the switch I/II pocket (SI/II-pocket) by structure-based agent design with nanomolar affinity. BI-2852 is mechanistically distinct from covalent KRASG12C inhibitor (binds to switch II pocket) and binds ten-fold more strongly to active KRASG12D versus KRASwt (740 nM vs 7.5 μM). BI-2852 blocks GEF, GAP, and effector interactions with KRAS, leading to inhibition of downstream signaling and an antiproliferative effect in KRAS mutant cells.

   

methyl (1s,2r,5r,6s,7s,8s,9r,12r)-5,12-bis(acetyloxy)-7-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecane-8-carboxylate

methyl (1s,2r,5r,6s,7s,8s,9r,12r)-5,12-bis(acetyloxy)-7-(benzoyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecane-8-carboxylate

C28H36O9 (516.2359206)


   

[(3s,4r,5s)-5-{[(2s,3r,5s,6r)-4,5-dihydroxy-2-[4-(2-hydroxyethyl)phenoxy]-6-(hydroxymethyl)oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl (2s)-2-methylbutanoate

[(3s,4r,5s)-5-{[(2s,3r,5s,6r)-4,5-dihydroxy-2-[4-(2-hydroxyethyl)phenoxy]-6-(hydroxymethyl)oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl (2s)-2-methylbutanoate

C24H36O12 (516.2206656000001)


   

2,3,11-tris(acetyloxy)-5,5,9-trimethyl-14-methylidene-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-7-en-15-yl acetate

2,3,11-tris(acetyloxy)-5,5,9-trimethyl-14-methylidene-6-oxotetracyclo[11.2.1.0¹,¹⁰.0⁴,⁹]hexadec-7-en-15-yl acetate

C28H36O9 (516.2359206)


   

11-isopropyl-4,7-dimethyl-18-(sec-butyl)-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),14,16,19(22)-octaene-2,9,16-triol

11-isopropyl-4,7-dimethyl-18-(sec-butyl)-6,13-dioxa-20-thia-3,10,17,22,23,24-hexaazatetracyclo[17.2.1.1⁵,⁸.1¹²,¹⁵]tetracosa-1(21),2,5(24),9,12(23),14,16,19(22)-octaene-2,9,16-triol

C24H32N6O5S (516.2154782)


   

5,8,12-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

5,8,12-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359206)


   

4,5,8-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

4,5,8-tris(acetyloxy)-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359206)


   

(1s,2r,5s,6s,8r,10s,11s,12r,14r,15r,16s,19s,21r)-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

(1s,2r,5s,6s,8r,10s,11s,12r,14r,15r,16s,19s,21r)-6-(furan-3-yl)-12,16,19-trihydroxy-5,11,15-trimethyl-3-oxo-9,17-dioxahexacyclo[13.3.3.0¹,¹⁴.0²,¹¹.0⁵,¹⁰.0⁸,¹⁰]henicosan-21-yl acetate

C28H36O9 (516.2359206)


   

(2s)-4-{5-hydroxy-8,8-dimethyl-2-oxo-4-propylpyrano[2,3-h]chromen-6-yl}-2-methyl-4-oxobutyl (2e)-3-phenylprop-2-enoate

(2s)-4-{5-hydroxy-8,8-dimethyl-2-oxo-4-propylpyrano[2,3-h]chromen-6-yl}-2-methyl-4-oxobutyl (2e)-3-phenylprop-2-enoate

C31H32O7 (516.2147921999999)


   

(1s,2r,4s,5r,6r,7s,9r)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

(1s,2r,4s,5r,6r,7s,9r)-4,5-bis(acetyloxy)-6-[(acetyloxy)methyl]-2,10,10-trimethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl benzoate

C28H36O9 (516.2359206)


   

4-[11a-(acetyloxy)-3a,6,6,9a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxypentanoic acid

4-[11a-(acetyloxy)-3a,6,6,9a-tetramethyl-3,4,7,10-tetraoxo-1h,2h,5h,5ah,8h,9h,11h-cyclopenta[a]phenanthren-1-yl]-4-hydroxypentanoic acid

C28H36O9 (516.2359206)


   

(1s,2s,5s,6s,7s,9r,12r)-12-(acetyloxy)-2-hydroxy-5-[(2-hydroxyacetyl)oxy]-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate

(1s,2s,5s,6s,7s,9r,12r)-12-(acetyloxy)-2-hydroxy-5-[(2-hydroxyacetyl)oxy]-2,6,10,10-tetramethyl-11-oxatricyclo[7.2.1.0¹,⁶]dodecan-7-yl (2e)-3-phenylprop-2-enoate

C28H36O9 (516.2359206)


   

[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-2-[4-(2-hydroxyethyl)phenoxy]-6-(hydroxymethyl)oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl (2s)-2-methylbutanoate

[(3s,4r,5s)-5-{[(2s,3r,4s,5s,6r)-4,5-dihydroxy-2-[4-(2-hydroxyethyl)phenoxy]-6-(hydroxymethyl)oxan-3-yl]oxy}-3,4-dihydroxyoxolan-3-yl]methyl (2s)-2-methylbutanoate

C24H36O12 (516.2206656000001)


   

9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl 2-methylbut-2-enoate

9,14-dihydroxy-3,4,5,15,16-pentamethoxy-9,10-dimethyltricyclo[10.4.0.0²,⁷]hexadeca-1(12),2,4,6,13,15-hexaen-8-yl 2-methylbut-2-enoate

C28H36O9 (516.2359206)